IMMIX Biopharma (IMMX) Looks Like it has Plenty of Room to Grow its Value
Good day biotech investors,
Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.
Current price $5.65/share (as of 10:00 am. EST 1-18-22)
After closing at $5.84/share in the Friday session, IMMX shares opened lower today at $5.55. The market indices are struggling this morning and we hope that will turn around. In the first 30 minutes of trading IMMX share are above the open but lag the prior sessions close.
IMMX is not the only development/clinical stage company with a novel platform for cancer treatment. I looked at a few of the others and came to two conclusions and maybe you will agree:
I think the IMMX SMARxT Platform has more potential.
IMMX has a lot of room to grow its value.
C4 Therapeutics (CCCC) MV $1.33B
Adaptimmune Therapeutics (ADAP) MV $515M
Immix Biopharma (IMMX) MV $44M
Biolata (BCAB) MV $465M
Upcoming event
An IMMX Investors Day Event, will be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to submit questions in advance. IMMX shareholders can submit and upload questions to be answered at the event. To submit questions, please visit https://immixbio.com/QA. The Q&A platform will remain open until 5:00pm ET on Thursday, January 20. The live webcast will be available on the Investor Relations website at https://immixbio.com/IR. Following the event, a replay of the event, as well as a transcript, will be available on the same website.
To me, hosting a Q&A session so soon after their IPO indicates a high level of confidence.
Stay tuned for my full report on IMMX coming tomorrow morning.
original report below
____________________
IMMX shares exploded two weeks ago and have maintained their higher pricing level. Why?
Good day everyone,
Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.
Current price $5.84/share (as of market close 1-14-22)
We wanted to report on IMMX because it's a new IPO in the biopharma sector and we want to explore their potential. The company announced that its shares began trading on the NASDAQ on December 16th and the IPO closed on December 20th with an offering of 4,200,000 shares of its common stock at a price of $5.00 per share, for gross proceeds of $21M.
The IPO is less that a month old and like often happens, the company shares declined over the first couple weeks to under $3.50/share. On January 3rd the company announced its lead product candidate, IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the treatment of pediatric cancer.
IMMX shares more than doubled on the news, closed that day at $5.78/share and have remained near that price range since. A quick check of the IMMX stock chart will show the narrow range the shares have traded in for the past two weeks. Will the company value stay in this narrow range? I think not, I believe it's going higher and what I say below is why.
Firstly, IMMX has a tiny share structure (7.5M outstanding and only 1.29M in the float) and insiders own 44.6% of the outstanding shares. Altium Capital Management is already in for an 8.27% stake. Competition for IMMX shares is intensifying.
As you read about the IMMX platform below, keep in mind that as of this writing, the company market value is less that $50M and compare that to other companies you know of with promising oncology treatments in development.
The second reason interest is growing in IMMX shares is their novel technology. IMMX is developing a new class of Tissue-Specific Therapeutics, or TSTx, which they believe will replace first-line therapies across a multitude of oncology indications.
That press release on January 3rd opened investor's eyes to the IMMX cancer treatment technology. It's new, novel, and quite amazing. As investor awareness grows, I believe the company will grow. To me, it seems like the FDA is already looking favorably toward the IMMX technology.
Their SMARxT Platform produces Tissue-Specific Therapies, which in cancer target all three components (1. cancer associated fibroblasts, 2. tumor-associated macrophages/immune cells, and 3. cancer itself), of the TME simultaneously, severing the critical lifelines between the tumor and its metabolic support.
You will learn more about the IMMX SMARxT Platform by visiting the resources I've listed below but, briefly, the IMMX technology starves a cancer tumor of the nutrients it needs to survive and grow, effectively killing it.
Just last Wednesday the company informed that "ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study." That 50% is an impressive positive response rate. The data was generated after 1 cycle of treatment as a monotherapy in first line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study. Clinical treatment for STS, is a $3 billion market expected to grow to $6.5 billion by 2030.
Just to underscore the significance of the animal study above, Doxorubicin, a cancer treatment that IMMX may compete with, one with over $1B in revenues, had a response rate of 0% after 1 cycle of treatment in the same study.
Watch this short video that describes the function of their IMX-110 product and review the presentation linked below to familiarize yourself with this new approach to cancer treatment. I'm certain that savvy investors are doing it.
In the chart below you can see the three products in development at IMMX. As a part of your due diligence, you can review the company presentation.
https://i.redd.it/5afe5v1e2hc81.gif
IMMX was incorporated in California in 2012 so they have been developing their technology for a while. They also have a wholly owned Australian subsidiary, Immix Biopharma Australia Pty Ltd., to conduct various pre-clinical and clinical activities for the development of product candidates.
The potential for growth in value at IMMX is not only likely, but I also believe it could be exponential. As you study their SMARxT Platform you may understand why the competition for that tiny 1.29M share float is getting competitive.
Stay tuned for our full report on IMMX.
Disclosure
No comments:
Post a Comment